Current Open Cancer Clinical Trials
Researchers at New England Hematology/Oncology and Dana-Farber Cancer Institute are collaborating on a variety of studies that examine cancer in many different medical areas. Below is a list of clinical trials currently enrolling subjects.
(last updated March 2016)
Helping Ourselves, Helping Others: The Young Women’s Breast Cancer Study
The aim of this study is to learn more about how breast cancer in young women affects their lives. We are particularly interested in young women’s emotional well-being, fertility concerns, sexual functioning, and physical health and treatment decisions.
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
The aim of this trial is to study how drugs used in chemotherapy work in different ways to stop the growth of tumor cells or by stopping them from spreading in patients with triple-negative breast cancer.
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/neu negative breast cancer
The aim of this study is to compare whether the addition of one year of everolimus to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR) positive and HER2-negative breast cancer.
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body.
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
This trial studies how well drugs, cisplatin or carboplatin works compared to observation in treating patients with basal-like triple-negative breast cancer following chemotherapy after surgery.
Randomized, double-blind, phase II trial of vitamin d supplementation in patients with previously untreated metastatic colorectal cancer
The aim of this study is to to evaluate the efficacy and safety of two doses of vitamin D supplementation in combination with standard chemotherapy in participants with previously-untreated metastatic colorectal adenocarcinoma. Standard treatment includes the chemotherapy combination of 5-FU, Leucovorin and Oxaliplatin (FOLFOX) with bevacizumab.
A Phase I Trial Of Intensity-Modulated Radiation Therapy (IMRT) Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Non-Small Cell Lung Cancer (NSCLC) And Limited-Stage Small Cell Lung Cancer (LS-SCLC).
This research study is examining the benefit of a novel radiation planning approach on the likelihood of developing severe esophagitis (irritation and inflammation of the esophagus) during the course of radiation therapy with concurrent chemotherapy which is associated with very painful and difficult swallowing.
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (ALCHEMIST)
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
This trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK.
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
This trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.
Phase II Trial of Combination of Elotuzumab and Lenalidomide +/-Dexamethasone in High-Risk Smoldering Multiple Myeloma
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab and lenalidomide+/- dexamethasone combination therapy.
A randomized, phase III study comparing conventional dose treatment using a combination of lenalidomide, bortezomib and dexamethasone (RVD) to high-dose treatment with peripheral stem cell transplant in the initial management of myeloma in patients up to 65 years of age
The aim of this research study is to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients with MGUS and Smoldering Multiple Myeloma
This research study is evaluating the effects of a mind body medicine intervention called the Relaxation Response Resiliency Program (3RP) on stress and stress related symptoms in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Phase III trial of enzalutamide (nsc # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer
The aim of this study is to compare the overall survival of patients with progressive metastatic castration resistant prostate cancer treated with either a) enzalutamide only or b) enzalutamide with abiraterone and prednisone.
Find a Doctor
Find primary care physicians and specialists.
Read Our 2016 Boston Marathon BlogFollow members of the Newton-Wellesley Hospital team as they share their training experiences.
» Read Blog
May 16: AAA Driver Improvement for Mature OperatorsJoin our lunchtime discussion on specific problem areas seniors encounter on the roadway every day.